<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00591890</url>
  </required_header>
  <id_info>
    <org_study_id>IBL1003</org_study_id>
    <nct_id>NCT00591890</nct_id>
  </id_info>
  <brief_title>Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans</brief_title>
  <official_title>Phase IB Study to Evaluate the Biological Activity of Indibulin Using Positron-Emission Tomography (PET) Scans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziopharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziopharm</source>
  <brief_summary>
    <textblock>
      Single arm, open label, Phase IB study of indibulin capsules in subjects with advanced solid&#xD;
      tumors; eligible subjects will have a baseline PET scan showing a standardized uptake value&#xD;
      (SUV) of ≥5.0 in ≥1 lesion on an 18F-FDG (fluorine-18-labeled deoxyglucose) scale.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>anti-tumor effect on PET Scan</measure>
    <time_frame>7 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxicities</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indibulin</intervention_name>
    <description>dose escalation of indibulin given twice daily for 21 days, to be repeated every 28 days.</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>ZIO-301</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological or cytological confirmation of advanced cancer, refractory to standard&#xD;
             therapies.&#xD;
&#xD;
          2. Received at least one prior therapy and requires additional treatment.&#xD;
&#xD;
          3. ≥18 years of age.&#xD;
&#xD;
          4. ECOG performance score ≤ 2 (see Appendix 3).&#xD;
&#xD;
          5. At least one measurable lesion as defined by RECIST (Response evaluation criteria in&#xD;
             solid tumors) guidelines (see Appendix 4). If the measurable disease is restricted to&#xD;
             a solitary lesion, its neoplastic nature should be confirmed by cytology/histology.&#xD;
             Measurable lesions must NOT have been in a previously irradiated field or injected&#xD;
             with biological agents.&#xD;
&#xD;
          6. PET scan showing a standardized uptake value (SUV) of ≥5.0 in at least 1 lesion on an&#xD;
             18F-FDG (fluorine-18-labeled deoxyglucose) scale.&#xD;
&#xD;
          7. Life expectancy ≥12 weeks.&#xD;
&#xD;
          8. Adequate bone marrow, liver and renal function as assessed by the following laboratory&#xD;
             requirements, to be conducted &lt;2 weeks prior to Day 1:&#xD;
&#xD;
               -  Creatinine ≤1.5 × upper limit of normal (ULN) or calculated creatinine clearance&#xD;
                  ≥50 cc/minute&#xD;
&#xD;
               -  Total bilirubin ≤1.5 × ULN&#xD;
&#xD;
               -  Alanine transaminase (ALT) and aspartate transaminase (AST) ≤2.5 × ULN&#xD;
&#xD;
               -  White blood cell count ≥3.0 × 109/L&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1.5 × 109/L&#xD;
&#xD;
               -  Platelets ≥100 × 109/L&#xD;
&#xD;
               -  Hemoglobin ≥10 g/dL&#xD;
&#xD;
          9. Ability to tolerate repeated blood sampling and adequate vascular access.&#xD;
&#xD;
         10. Serum glucose levels ≤200 mg/dL.&#xD;
&#xD;
         11. Provide written informed consent in compliance with ZIOPHARM policies and the&#xD;
             Independent Ethics Committee with jurisdiction over the site.&#xD;
&#xD;
         12. Subjects of childbearing potential must agree to use a barrier method of contraception&#xD;
             throughout the study and for 3 months after study drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. New York Heart Association (NYHA) functional class ≥3 or myocardial infarction within&#xD;
             6 months (see Appendix 5).&#xD;
&#xD;
          2. Uncontrolled diabetes mellitus&#xD;
&#xD;
          3. Uncontrolled cardiac arrhythmia other than asymptomatic atrial fibrillation.&#xD;
&#xD;
          4. Pregnancy and/or lactation.&#xD;
&#xD;
          5. Uncontrolled systemic infection (documented with microbiological studies)&#xD;
&#xD;
          6. Any other anti-cancer or immunological therapy during the study or within 4 weeks of&#xD;
             study entry. Mitomycin C or nitrosureas should not be given within 6 weeks of study&#xD;
             entry.&#xD;
&#xD;
          7. Radiotherapy during the study or within 3 weeks of study entry.&#xD;
&#xD;
          8. Surgery within 4 weeks of start of study drug excluding tumor biopsy for&#xD;
             pharmacodynamic parameters.&#xD;
&#xD;
          9. Investigational drug therapy outside of this trial during or within 4 weeks of study&#xD;
             entry.&#xD;
&#xD;
         10. History of an invasive second primary malignancy diagnosed within the previous 3&#xD;
             years, except for Stage I endometrial/cervical carcinoma or prostate carcinoma treated&#xD;
             surgically, and non-melanoma skin cancer.&#xD;
&#xD;
         11. Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the subject's participation in the study or evaluation of the study results&#xD;
&#xD;
         12. Any condition that is unstable or could jeopardize the safety of the subject and&#xD;
             his/her compliance with the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Lewis, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ziopharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <last_update_submitted>July 18, 2012</last_update_submitted>
  <last_update_submitted_qc>July 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

